AGP Executive Report
Last update: 7 hours agoEU Referendum Fallout: Iceland voted 52.5% No to 47.5% Yes against reopening EU accession talks, with voters citing fishing waters as too important to risk; the government says it will lean on the EEA relationship instead. Cross-Border Health Access (Liechtenstein): A new report highlights how Liechtenstein’s very strict abortion ban and an information ban push people to travel abroad for care, often with delays and limited local options across Austria and Switzerland. Rare Disease Treatment (EU/Norway/Iceland/Liechtenstein): The European Commission approved Acadia’s DAYBU (trofinetide) as the first and only EU-authorised treatment for Rett syndrome neurobehavioral symptoms for patients aged 5+; pricing and reimbursement talks now follow. Cancer Care Update: The EC also authorized Gilead’s Trodelvy plus Merck’s Keytruda for first-line metastatic triple-negative breast cancer in PD-L1 CPS≥10 patients, expanding options across the EU plus Norway, Iceland, and Liechtenstein. Care Support in Austria: Lower Austria opened its 2026 €1,000 Pflege- und Betreuungsscheck, including eligibility for certain foreign residents based on residence status and care needs. Mobility Rules Explained: Coverage revisits how Schengen border checks relate to EU free movement rules after renewed internal border controls in Europe.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
